News & analysis on the clinical development and manufacture of large molecule drugs
News from Lonza and SynteractHCR – People on the move
By Dan Stanton
- Last updated on
First up in this week’s offering comes from Lonza who, following its Annual General Meeting, has elected a few new members to its Board of Directors.
Werner Bauer (left), Thomas Ebeling (middle) and Antonio Trius (right) have all stepped up to replace Sir Richard Sykes, Gerhard Mayr and Jörg Reinhardt who did not stand for re-election.
And Lonza were featured in our sister publication last week in, reaffirming its commitment to its biosimilar joint venture with Teva. Read about it here.
Provider of Clinical Trial Materials and Services, Sharp Clinical Services, has announced Eric Bergmann will join them as Senior Director of Global Logistics.
Bergmann's seventeen years in the pharma industry has seen him have various roles at a number of firms, including Johnson & Johnson, Cardinal Health and, most recently, Yourway Transport Biopharma Services.
Joseph M. Morris, president of Sharp, said: “Eric’s rich experience working both as a contractor and as a sponsor, provide him with a unique perspective; this broad experience will enable Eric to contribute to the growth and development of our organization.”
A double signing now for CRO SynteractHCR as the company announces the appointment of Bill Pierce as its new Chief Information Officer and Dr. Richard Paul as Chief Medical Officer.
Pierce came direct from INC Research and has previously held leadership positions at Fidelity Investments and Goldman Sachs.
Paul, who will also serve as Vice President Medical/Regulatory Affairs, has over 23 years of experience in clinical research and prior to joining SynteractHR was executive vice president of drug development at QRxPharma.
And last month SynteractHCR was born when Harrison Clinical Research merged with Synteract. Click here to read more.
Next we go to molecular testing company AdvanDX who, according to CEO Dr. Dennis Langer, is “extremely pleased to welcome Heiner as the newest member of the AdvanDx board of directors.”
Yes, following a distinguished career in the diagnostics industry ex-President and CEO of Roche Molecular Systems, Dr. Heiner Dreismann has joined the board bringing a “valuable industry perspective” to the company.
And finally this week, ACM Global Central Laboratory has appointed Timo Jackle to its executive management team as vice president of clinical trials operations.
Jackle joins the company direct from Bausch & Lomb where he served in several roles, most recently executive director of global clinical trials operations.
According to Angela Panzarella, president of ACM Global Central Lab: “His strong focus on customer service and lengthy track record in improving business processes will no doubt be an asset to our clients.”